🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. TQJ230, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Apheresis

    phase 3 small molecule active

    1 trial

  2. TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma (GEA)

    phase 3 small molecule active

    1 trial

  3. TREPaed_10, TREPaed_5, TREPaed_0.5, TREPaed_2.5, TREPaed_1

    AOP Orphan Pharmaceuticals GmbH

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  4. TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  5. TV-1106

    Teva Pharma GmbH

    Growth Hormone-Deficiency

    phase 3 small molecule terminated

    4 trials

  6. TV-44749

    Teva Pharma GmbH

    Schizophrenia

    phase 3 small molecule completed

    3 trials

  7. TV-46000

    Teva Pharma GmbH

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  8. TV-46763

    Teva Pharma GmbH

    Pain

    phase 3 small molecule completed

    1 trial

  9. TVB-009

    Teva Pharma GmbH

    Osteoporosis, Postmenopausal

    phase 3 other completed

    1 trial

  10. Tacrolimus BID

    Teva Pharma GmbH

    Medication Adherence

    phase 3 small molecule active

    1 trial

  11. Tacrolimus capsule

    Astellas Pharma Inc

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  12. Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep

    Lacuna Pharma Pty Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  13. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  14. Tapinarof Cream 1%

    Teva Pharma GmbH

    Plaque Type Psorisis

    phase 3 small molecule completed

    1 trial

  15. Targretin Gel 1%

    LIGAND PHARMACEUTICALS INC

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  16. Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules

    Novartis Pharmaceuticals

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  17. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Jet Lag Type Insomnia

    phase 3 small molecule completed

    1 trial

  18. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Sleep Wake Disorders

    phase 3 small molecule active

    2 trials

  19. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  20. Tasimelteon Oral Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  21. Tbo-filgrastim

    Teva Pharma GmbH

    Healthy Participants

    phase 3 small molecule terminated

    1 trial

  22. Ted sc placebo, VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  23. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 3 small molecule terminated

    2 trials

  24. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Bacteremia

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources